ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Association between pupil size and response to atropine therapy in the Atropine Treatment of Myopia study (ATOM2).
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine if pupil size at baseline, on treatment, or change in pupil size while on atropine was associated with myopia progression.
methodsThis study utilized data from the ATOM2 study, a prospective, randomized, double-masked trial. 400 children were randomized to receive atropine 0.5%, 0.1%, or 0.01% daily in both eyes in a 2:2:1 ratio. Demographic data, as well as pupil size (PS) under photopic (300 lx) and mesopic (4 lx) conditions, axial length (AL), and spherical equivalent (SE) data at baseline and on follow-up, were collected.
resultsAt baseline, the mean photopic and mesopic pupil size was 3.96+/-0.63 mm and 4.48+/-0.66 mm, respectively. Pupils on higher doses were more dilated, with eyes with smaller PS at baseline having smaller PS on treatment. Multivariate analysis suggested that changes in axial length (AL) and spherical equivalent (SE) were strongly associated with age and change in PS, while PS on treatment was also associated with change in AL after controlling for sex, race and atropine dose. Receiver operating characteristic analysis, however, suggested that change in PS was a poor predictor of treatment response (area under curve: 0.53-0.69), with sensitivity being better than specificity. So while a larger change in PS (e.g. ≥2.5 mm in 6.0-8.9year old children, or ≥2 mm in older children) was more likely to be associated with a better result; having a smaller PS change did not necessarily suggest a poor result.
conclusionsA larger change in pupil size on treatment was associated with a better treatment response.
Indexed as
Identifiers
42474739What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.